Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rhG-CSF for Stem Cell Mobilization in Lymphoma
NCT05834751Unknown
- Start
- May 2023
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of pegfilgrastim in lymphoma. Primary endpoint: Mobilization success rate at 48 months. Status: unknown.
02
Drugs
pegfilgrastim
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT05834751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05834751.